On the upside
XenoPort (Nasdaq: XNPT) reported upbeat preliminary results for its relapsing-remitting multiple sclerosis and/or psoriasis treatment XP23829.
Oppenheimer affirmed its Outperform rating for Pier 1 Imports (NYSE: PIR) and lifted its price target to $25 from $20.
On the downside
Avian Securities analyst Mark Bachman downgraded First Solar (Nasdaq: FSLR) to a Negative rating citing reliability concerns.
Monster Worldwide (NYSE: MWW) reported a 3% annual increase to its U. S. employment index for September but a 2% sequential drop.
R. W. Baird analyst William Power downgraded Neutral Tandem (Nasdaq: IQNT) to a Neutral rating and cut its price target to $10 from $15.
In the broad market, advancing issues outpaced decliners by a margin of more than 9 to 7 on the NYSE while decliners edged out advancers by nearly 5 to 4 on Nasdaq. The Russell 2000 which tracks small cap stocks eased a point to 842.